The two medications target distinct neurobiological pathwaysone through incretin hormones and the other through opioid signalingwhich theoretically could produce complementary effects when combined
Both liraglutide and semaglutide have received FDA approval for the treatment of T2DM, obesity, and cardiovascular risk reduction [ Table 2 ]
Shipping delays
Currently, one type of GLP-1 medication comes in an oral tablet
Therefore, the design, discovery, and development of short and long-acting peptide-based GLP-1RAs, including small-molecule agonists are desirable for therapeutic applications beyond T2DM
But if you are very well-controlled with type 2 diabetes and your blood sugar goes a little bit higher, that may not be clinically that significant. Dominguez said the risk of elevated blood sugar levels would be a concern if someone with diabetes skips a dose